Dr. Falk Pharma GmbH — Sponsor Intelligence | 13 EU Trials

Filter these 13 trials by condition, phase, country and more.

Open in Search →

13 Registered trials

4 Recruiting

8 Completed trials

18 Countries active

4 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I (Other)

Phase III: 3 Phase II: 4 Phase I (Other): 6

100%

8 of 8 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Barrett's oesophagus 1 Oesophageal adenocarcinoma 1 Non-alcoholic steatohepatitis 1 Eosinophilic oesophagitis 1 Diabetic gastroparesis 1

Top IMPs

BUDESONIDE 3 NORUCHOLIC ACID 2 METHYL (E,6S)-7-[[1-[2-(2-ETHYLBUTYLAMINO)-2-OXOETHYL]-2-OXOPYRIDIN-3-YL]AMINO]-6-[(3-METHYLIMIDAZOLE-4-CARBONYL)AMINO]-7-OXOHEPT-2-ENOATE 1 NARONAPRIDE DIHYDROCHLORIDE TRIHYDRATE 1

All trials

13 total

A study to compare how the body absorbs 4 different forms of norucholic acid medicine (tablets, granules, and capsules) when taken with or w… Pending

2025-523778-17-00 Phase I (Other) 1 country
A phase II, double-blind, randomised, placebo-controlled trial to evaluate the efficacy and tolerability of a rectal treatment with budesoni… Recruiting

2024-519359-27-00 Phase II 2 countries BUDESONIDE
A phase 1 multi-centre, randomized, single-blind, steady-state study to evaluate pharmacokinetics, pharmacodynamics, safety and tolerability… Recruiting

2024-516197-30-00 Phase I (Other) 3 countries
A study to discover if ZED1227 can improve continued celiac disease symptoms despite a gluten-free diet Recruiting

2023-506150-21-00 Phase II 10 countries METHYL (E,6S)-7-[[1-[2-(2-ETHYLBUTYLAMINO)-2-OXOETHYL]-2-OXOPYRIDIN-3-YL]AMINO]-…
Clinical study to demonstrate the same clinical efficacy and tolerability of budesonide orodispersible tablets (taken twice a day compared t… Recruiting

2024-515229-26-00 Phase III 4 countries BUDESONIDE
An Open-label study of patients with primary sclerosing cholangitis (PSC) treated with norucholic acid tablets Ended

2024-514292-18-00 Phase III 10 countries NORUCHOLIC ACID
Evaluation of the Effect of Food, Itraconazole, and Rifampicin on the Single-Dose Pharmacokinetics of Naronapride. Ended

2024-520215-40-00 Phase I (Other) 1 country
Evaluation of the Effect of Itraconazole, Quinidine and Rifampicin on the Single-Dose Pharmacokinetics of ZED1227 Ended

2024-518734-87-00 Phase I (Other) 1 country
A clinical trial to learn how an investigational drug (norucholic acid) is absorbed, distributed, broken down, and removed from the body whe… Ended

2023-505862-27-00 Phase I (Other) 1 country
A study to characterize the pharmacokinetic profile of norucholic acid (NCA) in patients with primary sclerosing cholangitis (PSC) Ended

2023-507027-37-00 Phase I (Other) 4 countries
Clinical study to show if Naronapride tablets are safe and efficient for treatment of delayed stomach emptying and to find the optimal dose. Ended

2023-510195-31-00 Phase II 8 countries NARONAPRIDE DIHYDROCHLORIDE TRIHYDRATE
Double-blinded (treatment group unknown to physician and patient), randomised (treatment group allocated by chance) phase II trial on the ef… Ended

2023-507897-42-00 Phase II 7 countries BUDESONIDE
Double-blind, randomized, placebo-controlled, phase III study comparing norursodeoxycholic acid capsules with placebo in the treatment of pr… Ended

2023-510200-42-00 Phase III 9 countries NORUCHOLIC ACID

Showing 1–13 of 13 trials

← All sponsors A–Z